Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cfDNA for RAS Mutation Detection and Anti-EGFR Re-challenge in Advanced Colorectal Cancer
NCT04775862Phase 2Unknown
- Sponsor
- Ministry of National Guard Health Affairs
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, panitumumab in colorectal cancer (metastatic) (mCRC), sponsored by Ministry of National Guard Health Affairs. Status: unknown.
02
Drugs
cetuximabpanitumumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04775862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775862.